Part of Abbott’s Healon family of ophthalmic viscosurgical devices, the device intended for use as a surgical aid in cataract extraction and intraocular lens implantation.
It is a clear, viscous, protective gel formula that is intended to be injected into a patient’s eye to protect and coat the eye during surgery.
“Healon OVDs offer the surgeon the ultimate in control, clarity and ease-of-use during every step of the cataract procedure,” said Jim Mazzo, senior vice president, Abbott Medical Optics, in the release. “The U.S. approval of Healon EndoCoat OVD adds to a reliable portfolio of OVDs that has been known and trusted for more than 25 years and proven safe worldwide.”
Abbott is headquartered in Chicago.
Related Articles on FDA Clearances:
ProPep Surgical Receives FDA Clearance for Nerve Monitoring System
Ultrasonix Medical Receives FDA Approval for Needle Guidance Technology
Synergetics Receives FDA Clearance for Versavit Vitrectomy System
